Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024

2 hours ago 1

Author of the article:

Published Nov 15, 2024 • 2 minute read

New data highlights the safety and efficacy of a new outpatient self-administered therapy intended to assist in the management of fluid overload in CHF, liver, and kidney disease patients

HENDERSON, Nev. — Corstasis Therapeutics Inc., a clinical-stage biotechnology company pioneering outpatient therapies for fluid overload (edema) associated with congestive heart failure (CHF), liver disease, and chronic kidney disease, today announced that data from its pivotal trial of the bumetanide nasal spray (RSQ-777-02) will be presented at the upcoming American Heart Association’s (AHA) annual Scientific Sessions in Chicago, Illinois, November 16-18, 2024.

Advertisement 2

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account.
Share your thoughts and join the conversation in the comments.
Enjoy additional articles per month.
Get email updates from your favourite authors.

THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account
Share your thoughts and join the conversation in the comments
Enjoy additional articles per month
Get email updates from your favourite authors

Sign In or Create an Account

Article content

“We are honored to share the findings of our pivotal trial at this year’s AHA Scientific Sessions,” said Benjamin Esque, CEO of Corstasis Therapeutics, Inc. “These results mark a significant milestone in our commitment to delivering easy-to-use, outpatient solutions that help clinicians address the challenges of managing edema in CHF and other serious conditions. Our goal is to enhance health equity by providing accessible, outpatient non-oral diuresis options, particularly benefiting patients in rural and underserved communities.”

The presentation, titled “Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)”, will be featured during a late-breaking science session from 8:30-8:40 AM CST on November 18. The data will cover key aspects of the study, including safety, efficacy, pharmacokinetics, and pharmacodynamics of the nasal spray formulation versus traditional oral and intravenous bumetanide.

About Bumetanide Nasal Spray (BNS)

Bumetanide Nasal Spray (BNS) is an investigational parenteral diuretic option for congested patients with CHF, liver, and kidney disease. BNS leverages a simple, easy-to-use nasal delivery system enabling patients to self-administer therapy at home.

About Corstasis Therapeutics Inc.

Corstasis Therapeutics is dedicated to developing innovative, patient-centered therapies that enhance the quality of life for individuals affected by fluid overload in CHF, liver disease, and chronic kidney disease. By focusing on common sense outpatient solutions, Corstasis seeks to optimize outcomes, reduce hospital admissions, readmissions and improve accessibility to essential treatments for diverse patient populations.

Corstasis. Home is Where the Heart is. #homeiswheretheheartis #AHA2024

For more information, visit www.corstasis.com or connect with Corstasis on LinkedIn [ https://www.linkedin.com/company/corstasis-therapeutics/] and X [ https://x.com/corstasis].